Skip to search formSkip to main contentSkip to account menu

romosozumab

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Osteoporosis is characterized by induced bone mass and deterioration of the skeletal microstructural, which weakens bone strength… 
2019
2019
Osteoporosis is a condition of compromised bone quality and bone density increasing the chances of fracture. In osteoporotic bone… 
2017
2017
EULAR 2017: Romosozumab reduces the risk of clinical vertebral fractures in postmenopausal women with osteoporosis by as much as… 
2017
2017
Treatment with sclerostin antibody (romosozumab) increases bone formation while reducing bone resorption, leading to increases in… 
2016
2016
Blocking sclerostin (an osteocyte-derived negative regulator of bone formation) increases bone formation and reduces bone… 
2014
2014
Sclerostin is an osteocyte-secreted glycoprotein that inhibits bone formation. By binding to sclerostin, the monoclonal antibody… 
2014
2014
Results of a Phase II study suggest that romosozumab significantly increases bone mineral density (BMD) in the lumbar spine…